Market Place
Sourcing Support
Myovant endometriosis survey shows crippling effect on women
19 May 2023 //
FIERCE PHARMA
Sumitomo Pharma tidies up 7 units into 1 combined U.S. entity
03 Apr 2023 //
FIERCE BIOTECH
Sumitovant Biopharma Acquires Myovant Sciences in $1.7B Deal
10 Mar 2023 //
CONTRACT PHARMA
Myovant Announces Updates and Financial Results for Third Fiscal Quarter 2022
26 Jan 2023 //
GLOBENEWSWIRE
Myovant Sciences Investor Alert by the Former Attorney General of Louisiana
25 Jan 2023 //
BUSINESSWIRE
Myovant, Pfizer debut first branded campaign for prostate cancer med Orgovyx
13 Jan 2023 //
ENDPTS
Myovant Sciences Announces Corporate Updates and Financial Results for Q2 2022
26 Oct 2022 //
GLOBENEWSWIRE
Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant
25 Oct 2022 //
BIOSPACE
Myovant Sciences Cancels Second Quarter Earnings Conference Call
24 Oct 2022 //
GLOBENEWSWIRE
Myovant Announces New Employment Inducement Grants Under NYSE Rule 303A.08
18 Oct 2022 //
GLOBENEWSWIRE
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call
14 Oct 2022 //
GLOBENEWSWIRE
Myovant rejects Sumitomo`s buyout offer—at least for now
04 Oct 2022 //
FIERCEPHARMA
Myovant`s Board Confirms Sumitovant & Sumitomo to Acquire Remaining Shares
02 Oct 2022 //
GLOBENEWSWIRE
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships
16 Sep 2022 //
GLOBENEWSWIRE
Myovant Sciences Announces New Inducement Grants Under NYSE Rule 303A.08
16 Sep 2022 //
GLOBENEWSWIRE
Myovant Sciences to Participate at Upcoming Investor Conferences
02 Sep 2022 //
GLOBENEWSWIRE
Myovant, Pfizer`s Myfembree nabs FDA nod for endometriosis
09 Aug 2022 //
FIERCEPHARMA
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE
05 Aug 2022 //
GLOBENEWSWIRE
FDA Action Alert: Coherus, Sanofi and Regeneron, Acadia, Myovant and Pfizer
01 Aug 2022 //
BIOSPACE
Myovant touts Pfizer-partnered drug launch plans
30 Jul 2022 //
FIERCEPHARMA
Myovant Sciences Announces Financial Results for First Fiscal Quarter 2022
27 Jul 2022 //
GLOBENEWSWIRE
Myovant Sciences Announces New Employment Inducement Grants
18 Jul 2022 //
GLOBENEWSWIRE
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call
13 Jul 2022 //
GLOBENEWSWIRE
Myovant Sciences and Pfizer Announce Publication in The Lancet
17 Jun 2022 //
GLOBENEWSWIRE
Myovant Announces New Employment Inducement Grants Under NYSE Rule 303A.08
16 Jun 2022 //
GLOBENEWSWIRE
Myovant Sciences Generic Orgovyx (Relugolix) Receives Approval in Europe
10 Jun 2022 //
EMA
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Conference
03 Jun 2022 //
GLOBENEWSWIRE
Myovant Sciences and Pfizer Announce FDA Acceptance of sNDA for MYFEMBREE
02 Jun 2022 //
GLOBENEWSWIRE
Myovant and Accord Healthcare enter licence agreement to commercialise Orgovyx
13 May 2022 //
EXPRESS PHARMA
Myovant Sciences Reports Financial Results for Fourth Fiscal Quarter, FY22
10 May 2022 //
GLOBENEWSWIRE
Myovant Sciences and Accord Healthcare Enter into License Agreement for ORGOVYX
09 May 2022 //
GLOBENEWSWIRE
Myovant, Pfizer Provide Update on sNDA for MYFEMBREE in Endometriosis
06 May 2022 //
GLOBENEWSWIRE
EC Approves Myovant`s ORGOVYX for Advanced Hormone-Sensitive Prostate Cancer
29 Apr 2022 //
GLOBENEWSWIRE
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021
26 Apr 2022 //
GLOBENEWSWIRE
Myovant Stumbles on FDA Concerns Over Pfizer-Partnered Endometriosis Drug
12 Apr 2022 //
BIOSPACE
Myovant and Pfizer Provide Update on sNDA for MYFEMBREE in Endometriosis
12 Apr 2022 //
GLOBENEWSWIRE
EMA expands nods for BMS, Eli Lilly, Novartis drugs
26 Feb 2022 //
FIERCEPHARMA
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX (relugolix)
25 Feb 2022 //
GLOBENEWSWIRE
Myovant Sciences to Present at Upcoming Investor Conferences
07 Feb 2022 //
PRESS RELEASE
Myovant Sciences: Financial Results for Q3 of FY 2021 & Corporate Updates
26 Jan 2022 //
GLOBENEWSWIRE
Myovant Sciences Announces Prelim Financial Results for Q3 of Fiscal Year 2021
10 Jan 2022 //
GLOBENEWSWIRE
Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx
23 Nov 2021 //
GLOBENEWSWIRE
Myovant Sciences Announces Financial Results for Second Quarter
26 Oct 2021 //
GLOBENEWSWIRE
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy
19 Oct 2021 //
GLOBENEWSWIRE
FDA accepts sNDA from Myovant Sciences and Pfizer for MYFEMBREE
09 Sep 2021 //
GLOBENEWSWIRE
Myovant - European Commission Approval for RYEQO Treatment ofUterine Fibroid
20 Jul 2021 //
GLOBENEWSWIRE
Myovant, Gedeon Richter’s uterine fibroids med Ryeqo bags EU approval
20 Jul 2021 //
PHARMATIMES
Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference
14 Jul 2021 //
GLOBENEWSWIRE
FDA approves Pfizer, Myovant’s uterine fibroids drug Myfembree
27 May 2021 //
PHARMATIMES
As FDA clears relugolix for uterine fibroids, Myovant, Pfizer gear up
27 May 2021 //
ENDPTS
Cleveland Clinic Researchers Identify New Drug Target for Treating Aggressive
26 May 2021 //
CLEVELANDCLINIC
Pfizer, Myovant begin dosing in relugolix contraceptive study
14 Apr 2021 //
PHARMTIMES
MYOVANT SCIENCES AND PFIZER ANNOUNCE FIRST PARTICIPANT DOSED IN PHASE 3
13 Apr 2021 //
PRESS RELEASE
Myovant Sciences Announces European Medicines Agency Validation of Marketing
29 Mar 2021 //
BIOSPACE
Myovant adds relugolix data in uterine fibroids ahead of June PDUFA
26 Mar 2021 //
ENDPTS
Relugolix shows potential long-term benefit in women with uterine fibroids
25 Mar 2021 //
PHARMATIMES
Pfizer and Myovant report positive data from uterine fibroid therapy trial
25 Mar 2021 //
CLINICALTRIALSARENA
MYOVANT SCIENCES AND PFIZER ANNOUNCE PUBLICATION IN THE NEW ENGLAND JOURNAL
17 Feb 2021 //
PRESS RELEASE
Myovant beefs up data package in NDA #3, boosting its case for longterm
26 Jan 2021 //
ENDPTS
Myovant leans on partner Pfizer as it dives into Orgovyx launch
26 Jan 2021 //
FIERCE PHARMA
